The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Lifebit, gen-t, and Omica.bio partner to diversify genomic research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Lifebit, gen-t, and Omica.bio have partnered to help diversify genomic research and reduce health inequality in Latin America. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy. 
By Michael P. Castro
Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
By Melinda Krigel
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account